Johnson & Johnson: Q4 EPS down 11%

(CercleFinance.com) - Johnson & Johnson reports adjusted EPS for the last three months of 2024 down 10.
9% at $2.04, a level roughly in line with expectations, although burdened to the tune of 22 cents by IPR&D charges acquired in connection with the V-Wave acquisition.

At just over $22.5bn, the healthcare group's revenues rose by 5.3% on a reported basis, with a 6.7% increase in operating revenues (including +10% in the US and +2.5% internationally).

With FY 2024 adjusted EPS of $9.98 and operating revenue growth of 5.9%, J&J is targeting FY 2025 guidance ranges of $10.75 to $10.95 and 2.5% to 3.5% respectively.


Copyright (c) 2025 CercleFinance.com. All rights reserved.